ABIOMED Inc logo

ABMD - ABIOMED Inc Share Price

$285.92 -15.3  -5.1%

Last Trade - 08/03/21

Large Cap
Market Cap £9.84bn
Enterprise Value £9.49bn
Revenue £587.3m
Position in Universe 743rd / 6647
Unlock ABMD Revenue
Relative Strength (%)
1m -5.14%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -22.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
230.3 329.5 445.3 593.7 769.4 840.9 837.3 998.1 +29.6%
+1,401 -68.0 +37.3 +149.6 +92.6 -19.6 +6.67 +2.20
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 31 December 2020, ABIOMED,Inc. revenues decreased 4% to $606.3M. Net income decreased1% to $168.7M. Revenues reflect Impella product revenuesegment decrease of 5% to $576M, United States segmentdecrease of 7% to $496M. Net income also reflects OtherResearch and development increase of 25% to $84.8M(expense), Investment income, net decrease of 37% to $5.7M(income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for ABMD
Graphical History


ABMD Revenue Unlock ABMD Revenue

Net Income

ABMD Net Income Unlock ABMD Revenue

Normalised EPS

ABMD Normalised EPS Unlock ABMD Revenue

PE Ratio Range

ABMD PE Ratio Range Unlock ABMD Revenue

Dividend Yield Range

ABMD Dividend Yield Range Unlock ABMD Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ABMD EPS Forecasts Unlock ABMD Revenue
Profile Summary

ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company's product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company's products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.

Last Annual March 31st, 2020
Last Interim December 31st, 2020
Incorporated June 4, 1987
Public Since July 29, 1987
No. of Shareholders: 397
No. of Employees: 1,536
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index Nasdaq Composite , S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector),
Exchange NASDAQ Global Select Market
Shares in Issue 45,230,966
Free Float (0.0%)
Eligible for
ABMD Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ABMD
Upcoming Events for ABMD
Wednesday 28th April, 2021 Estimate
Q4 2021 ABIOMED Inc Earnings Release
Frequently Asked Questions for ABIOMED Inc
What is the ABIOMED Inc share price?

As of 08/03/21, shares in ABIOMED Inc are trading at $285.92, giving the company a market capitalisation of £9.84bn. This share price information is delayed by 15 minutes.

How has the ABIOMED Inc share price performed this year?

Shares in ABIOMED Inc are currently trading at $285.92 and the price has moved by 94.95% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the ABIOMED Inc price has moved by 53.77% over the past year.

What are the analyst and broker recommendations for ABIOMED Inc?

Of the analysts with advisory recommendations for ABIOMED Inc, there are there are currently 3 "buy" , 4 "hold" and 0 "sell" recommendations. The overall consensus recommendation for ABIOMED Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will ABIOMED Inc next release its financial results?

ABIOMED Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the ABIOMED Inc dividend yield?

ABIOMED Inc does not currently pay a dividend.

Does ABIOMED Inc pay a dividend?

ABIOMED Inc does not currently pay a dividend.

When does ABIOMED Inc next pay dividends?

ABIOMED Inc does not currently pay a dividend.

How do I buy ABIOMED Inc shares?

To buy shares in ABIOMED Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of ABIOMED Inc?

Shares in ABIOMED Inc are currently trading at $285.92, giving the company a market capitalisation of £9.84bn.

Where are ABIOMED Inc shares listed? Where are ABIOMED Inc shares listed?

Here are the trading details for ABIOMED Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ABMD
What kind of share is ABIOMED Inc?

Based on an overall assessment of its quality, value and momentum, ABIOMED Inc is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a ABIOMED Inc share price forecast 2021?

Shares in ABIOMED Inc are currently priced at $285.92. At that level they are trading at 25.49% discount to the analyst consensus target price of 0.00.

Analysts covering ABIOMED Inc currently have a consensus Earnings Per Share (EPS) forecast of 4.813 for the next financial year.

How can I tell whether the ABIOMED Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ABIOMED Inc. Over the past six months, the relative strength of its shares against the market has been -3.47%. At the current price of $285.92, shares in ABIOMED Inc are trading at 5.57% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the ABIOMED Inc PE Ratio?

The ABIOMED Inc PE ratio based on its reported earnings over the past 12 months is 67.26. The shares are currently trading at $285.92.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of ABIOMED Inc?

ABIOMED Inc's management team is headed by:

Dorothy Puhy - LED
Michael Minogue - CHM
David Weber - COO
Eric Rose - IND
Andrew Greenfield - VPR
Martin Sutter - IND
Michael Howley - VPR
Jeannine Rivet - IND
Todd Trapp - CFO
Marc Began - VPR
Myron Rolle - DRC
Who are the major shareholders of ABIOMED Inc?

Here are the top five shareholders of ABIOMED Inc based on the size of their shareholding:

The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 10.62% (4.80m shares)
Baillie Gifford & Co. Investment Advisor
Percentage owned: 6.73% (3.04m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 5.71% (2.58m shares)
PRIMECAP Management Company Investment Advisor
Percentage owned: 4.53% (2.05m shares)
Renaissance Technologies LLC Hedge Fund
Percentage owned: 4.41% (1.99m shares)
Similar to ABMD
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.